

BIOARCTIC AB (PUBL)
NASDAQ STOCKHOLM: BIOA B

BioArctic Corporate Presentation

Jefferies Healthcare Conference

New York, June 4, 2019


Gunilla Osswald, PhD, CEO



Disclaimer

- This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such data is provided as at the date of this presentation and is subject to change without notice.
- This presentation includes forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause BioArctic’s actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this presentation and BioArctic expressly disclaims any obligation or undertaking to release any update of, or revisions to, any forward-looking statement in this presentation, as a result of any change in BioArctic’s expectations or any change in events, conditions or circumstances on which these forward-looking statements are based.
- This presentation does not constitute or form part of, and should not be construed as, an offer or invitation for the sale of or the subscription of, or a solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it or the fact of its distribution form, or be relied on in connection with, any offer, contract, commitment or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of BioArctic.
- The information in this presentation has not been independently verified.
- No regulatory body in Sweden or elsewhere has examined, approved or registered this presentation.

BioArctic – a unique Swedish biopharma company



High unmet patient need for disease-modifying treatments for Alzheimer's and Parkinson's diseases creates **large commercial opportunity**



World-class research and development driven organization with basis in founder's breakthrough discoveries and fruitful collaborations with leading **academic researchers** generating **innovative projects**




Attractive and well-balanced project portfolio with projects from discovery through Phase 3 and combination of both proprietary projects with substantial marketing and out-licensing potential and partnered projects generating income



Well-financed with >1 BSEK (>100 MUSD) in cash, **positive financial results** during the last six years and **valuable collaboration agreements** totaling 9.3 BSEK (~1 BUSD) plus royalties

Focused in 4 key areas within Central Nervous System diseases to deliver innovative therapies

ALZHEIMER'S DISEASE



BAN2401

- Strong clinical Phase 2b results in early Alzheimer's
- Phase 3 confirmatory study started by partner



Discovery stage programs

- 3 additional preclinical stage disease modifying antibody programs with different mechanisms

PARKINSON'S DISEASE



ABBV-0805

- Phase 1 study ongoing by partner

abbvie

Discovery stage projects

- Preclinical stage projects in research collaboration partnered with

abbvie

COMPLETE SPINAL CORD INJURY



SC0806

- Phase 1 safety evaluated and Phase 2 started

DIAGNOSTICS AND TECHNOLOGY




Imaging and biochemical biomarkers

- For Alzheimer's and Parkinson's diseases



Blood-Brain Barrier Technology

- Developing new technology platform to facilitate the passage of biologics over the blood-brain barrier



Targeting the toxic forms of misfolded proteins is important when designing therapies for neurodegenerative diseases



Alzheimer's disease: misfolded amyloid beta results in amyloid plaques



Parkinson's disease: misfolded alpha-synuclein results in Lewy Bodies



Experienced management, innovative scientists and collaborations with universities to bring forward the next groundbreaking therapy

Experienced Management

GUNILLA OSSWALD, PhD

CEO

Former VP AstraZeneca (portfolio, projects, clinical, marketing)

30 years relevant experience



HANS BASUN, Professor, MD

VP CMO

Geriatrician at Memory Clin, Uppsala former AstraZeneca (clinical development)

35 years relevant experience



CHRISTER MÖLLER, PhD

VP CSO

Extensive experience from small biotech (research & development)

20 years relevant experience



JOHANNA FÄLTING, PhD

VP Translational Science & Pharmacology

Former AstraZeneca R&D (discovery & drug projects)

15 years relevant experience



MIKAEL MOGE, PhD

VP CMC and Protein Chemistry

Former AstraZeneca (Pharmaceutical Development) and Syntagon (Head Development & Pilot Plant)

20 years relevant experience



NORA SJÖDIN

VP Regulatory Affairs

Former Pharmalink, NDA Regulatory Service, AstraZeneca

20 years relevant experience



LARS LANNFELT, Professor, MD

Co-founder, Senior VP University Collaborations

Senior Professor, Uppsala University
Discovered the Swedish and Arctic mutations in Alzheimer's Disease

35 years relevant experience





Innovative Scientists



Collaboration with Universities



Attractive and well-balanced project portfolio combines fully-financed partner projects and cutting-edge proprietary projects

	Product candidate	Indication	Partner	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	
Neurodegenerative Diseases	BAN2401: anti-A β antibody	Alzheimer's Disease		→					
	BAN2401: anti-A β antibody	Down's Syndrome ² Traumatic Brain Injury ²	—	→					
	BAN2401 BACK-UP: anti-A β antibody	Alzheimer's Disease		→					
	AD1801: Undisclosed information	Alzheimer's Disease	—	→					
	AD1502: Undisclosed information	Alzheimer's Disease	—	→					
	AD1503: Undisclosed information	Alzheimer's Disease	—	→					
	ABBV-0805³: anti- α -synuclein antibody	Parkinson's Disease	abbvie	→					
	PD1601: anti- α -synuclein antibody	Parkinson's Disease	abbvie	→					
	PD1602: anti- α -synuclein antibody	Parkinson's Disease	abbvie	→					
Diagnostics & Technology	IMAGING AND BIOCHEMICAL BIOMARKERS: Aβ	Alzheimer's Disease	—	→					
	IMAGING AND BIOCHEMICAL BIOMARKERS: α-synuclein	Parkinson's Disease	abbvie	→					
	BBB-TECHNOLOGY: blood-brain barrier	Multiple application areas	—	→					
Spine	SC0806: FGF1/medical device	Complete Spinal Cord Injury	—	→					

as of March 31, 2019

- 1) Partner with Eisai on BAN2401 for treatment of Alzheimer's disease. Eisai partnered with Biogen on BAN2401 in 2014
- 2) Dementia and cognitive impairment associated with Down's syndrome and Traumatic Brain Injury
- 3) AbbVie in-licensed BAN0805 in late 2018 and will continue to develop BAN0805, now with the designation ABBV-0805

Long-standing and extensive partnerships

Alzheimer's disease

Partner Track Record




Discovered and developed world's best selling medicine for symptoms in Alzheimer's



10+ projects in dementia

Currently in development

Collaboration and license



Royalties
High single digit %

- BioArctic retains rights to BAN2401 in other indications and option to market in the Nordics

Parkinson's disease

Partner Track Record



World's all time best selling medicine (BUSD 20)




10 different indications in immunology

Approved product for symptoms associated with Parkinson's disease



Collaboration and license



Royalties
Tiered %

- AbbVie global rights to alpha-synuclein portfolio for all indications

Sources: Eisai, AbbVie and BioArctic corporate information

BioArctic has a strong financial profile

- Listed on Nasdaq Stockholm Mid Cap, market capitalization of SEKbn 6.7 (~700 MUSD)






- More than 1 billion SEK (100 MUSD) in cash
- Equity ratio at 73 percent



- Positive financial results during the last 6 years
- Expected 2019 operating costs 190-250 MSEK




- Significant funding from partner research collaborations and license agreements, as well as grants
- Total potential collaboration deal value of ~SEKbn 9.6 (~1 BUSD)* of which ~SEKbn 1.3 (~135 MUSD) received
- Additional future royalties potential
- Milestone payments one-time nature explain fluctuations in financial results



* Recalculated to SEK from Euro and US dollar with valid exchange rate on May 23 2019

BAN2401: potential disease modifying antibody for Alzheimer's disease with strong Phase 2b results now in Phase 3

High Unmet Medical Need



BAN2401 unique profile

Unique and targeted binding profile

- Highly selective for toxic forms of misfolded Abeta (oligomers/protofibrils)

Unique clinical fingerprint

- Rapid onset of clinical effect
- Consistent effects
- No titration required due to low frequency of ARIA-E

BAN2401 has strong Phase 2b results

- **Large trial:** 856 early Alzheimer's patients
- **Consistent effects** on clinical outcomes, imaging and neurodegenerative biomarkers
- **Effect increase over time**
- **Good safety profile**

Eisai announced 3 clinical trials underway

1. **Confirmatory Phase 3 study** ("Clarity AD") started
 - Primary endpoint final readout expected mid-2022
2. Phase 2b open label extension ongoing
3. Secondary prevention study ("A45 Study") in planning

ABBV-0805: potential disease modifying antibody for Parkinson's disease with strong preclinical results now in Phase 1

High Unmet Medical Need



2nd most common neurodegenerative disease

6.2 million people with Parkinson's in 2015

Younger patient group, still at working age

Unique profile

Unique and targeted binding profile


- Highly selective for toxic forms of misfolded alpha-synuclein (oligomers/protofibrils)

Built on genetic and pathology rationale


- Alpha-synuclein mutations lead to Parkinson's
- Alpha-synuclein oligomers/protofibrils are elevated in Parkinson's

Preclinical proof of concept

Reduction of neurotoxic alpha-synuclein oligomers/protofibrils



Delays disease progression and increases lifespan



ABBV-0805 in clinical development

- Phase 1 with ABBV-0805 ongoing by AbbVie
- BioArctic will deliver follow-up antibodies in the continued collaboration with AbbVie


SC0806: potential regenerative treatment for Complete Spinal Cord Injury in Phase 2

High Unmet Medical Need



No treatment for chronic injury

People with paralysis



- Significant quality of life issues
- More common among younger men
- Orphan Drug designation in US and EU for SC0806

Preclinical proof of concept and initial clinical safety


Preclinical model showed ¹⁾:

- Nerve regeneration
- Electrophysiology restored
- Motor function improved

Phase 1 in patients:

- Safety evaluation supported progression into Phase 2

SC0806 makes nerve regeneration possible



Growth factor FGF1

Peripheral nerve autografts

Biodegradable device




SC0806 in Phase 2

- Phase 2 ongoing in patients with Complete Spinal Cord Injury
Interim analysis expected 1H2020
- EU Horizon 2020 research and innovative program ²⁾

Advancing diagnostics and technology platforms to fuel pipeline

ALZHEIMER'S DISEASE

Antibody-based imaging (PET)



Biochemical biomarkers




PARKINSON'S DISEASE

Antibody-based imaging (PET)

Biochemical biomarkers


NEW TECHNOLOGY PLATFORM

Multi-specific antibodies facilitate passage over the Blood-Brain Barrier



Upcoming news flow

ALZHEIMER'S DISEASE



BAN2401 (Eisai)

- Present data at international congresses incl. AAIC in July
- Phase 3 confirmatory study results mid-2022
- Phase 2b open label extension study results
- Secondary prevention study start 2020

Discovery stage programs

- Preclinical development

PARKINSON'S DISEASE



ABBV-0805 (AbbVie)

- Complete Phase 1 study

Discovery stage projects

- Continue development in AbbVie collaboration

COMPLETE SPINAL CORD INJURY



SC0806

- Phase 1/2 study interim analyses of safety and efficacy

DIAGNOSTICS AND TECHNOLOGY



Blood-Brain Barrier Technology

- Expansion and continued development